ArticleAmerican journal of cancer research2026
Serum USP1 and PD-L1 levels independently predict treatment response and prognosis in cervical cancer: a retrospective cohort study.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a common malignant tumor with highly variable treatment outcomes, and the combined predictive value of serum ubiquitin-specific protease 1 (USP1) and programmed death ligand 1 (PD-L1) has been rarely investigated. This retrospective study included 102 cervical cancer patients treated between July 2022 and July 2024, who were classified into treatment-sensitive and treatment-resistant groups according to RECIST 1.1 criteria. After propensity score matching (1:1, caliper 0.02) for age, FIGO (International Federation of Gynecology and Obstetrics) stage, tumor diameter, lymph node status, and serum biomarkers, 84 patients (42 per group) were analyzed. Serum USP1 and soluble PD-L1 levels were measured by ELISA, and logistic regression, Kaplan-Meier curves, and Cox models were used for analysis. The resistant group showed significantly higher USP1 (38.62±9.43 vs. 29.86±8.24 pg/mL,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.